Production (Stage)
E
Arrowhead Pharmaceuticals, Inc. ARWR
$15.13 -$0.26-1.69% NASDAQ
Recommendation
Prev Close
$15.13
Volume
1,230,387
Avg Vol (90D)
1,969,852
Market Cap
$2.09B
Dividend & Yield
--
52-Week Range
$9.57 - $30.41
P/E (TTM)
--
EPS (TTM)
-$1.39
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Hold at StockNews.com
5/24/2025 - MarketBeat
Research Analysts Set Expectations for ARWR FY2025 Earnings
5/24/2025 - MarketBeat
Woodline Partners LP Cuts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
5/24/2025 - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright
5/22/2025 - MarketBeat
Rafferty Asset Management LLC Cuts Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
5/22/2025 - MarketBeat
Arrowhead Pharmaceuticals (ARWR, $15.31) RSI Indicator left the overbought zone on May 21, 2025
5/22/2025 - Tickeron - Stocks
Arrowhead Pharmaceuticals (ARWR, $16.29) RSI Indicator left the overbought zone on May 20, 2025
5/21/2025 - Tickeron - Stocks
Silvercrest Asset Management Group LLC Grows Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
5/21/2025 - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $4.56 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
5/21/2025 - MarketBeat
BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
5/21/2025 - MarketBeat
Tema Etfs LLC Takes $1.16 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
5/20/2025 - MarketBeat
Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
5/19/2025 - MarketBeat
Sphera Funds Management LTD. Purchases New Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
5/18/2025 - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by Analysts
5/18/2025 - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings Beat
5/15/2025 - MarketBeat
Chardan Capital Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
5/15/2025 - MarketBeat
Hudson Bay Capital Management LP Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
5/15/2025 - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings Results
5/14/2025 - MarketBeat
Integral Health Asset Management LLC Invests $5.17 Million in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
5/14/2025 - MarketBeat
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry
5/14/2025 - Simply Wall St
Arrowhead Pharmaceuticals (ARWR, $15.28) price may drop as it broke higher Bollinger Band on May 13, 2025
5/14/2025 - Tickeron - Stocks
Futures Dip As Torrid Squeeze Pauses Ahead Of CPI Report
5/13/2025 - Zero Hedge
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from RBC Capital
5/13/2025 - TipRanks Financial Blog
Arrowhead Pharmaceuticals (ARWR, $13.97) price moved above its 50-day Moving Average on May 12, 2025
5/13/2025 - Tickeron - Stocks
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...
5/13/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$545.21M
EBITDA (TTM)
-$97.43M
EBIT (TTM)
-$118.55M
Net Income (TTM)
-$143.97M
Balance Sheet
Total Assets (Q)
$1.57B
Total Debt (Q)
$740.51M
Total Liabilities (Q)
$889.27M
Book Value Per Share (Q)
$4.95
Cash Flow
Cash from Operations (TTM)
$61.15M
Cash from Investing (TTM)
-$559.28M
Cash from Financing (TTM)
$552.49M
Net Change in Cash (TTM)
$58.01M
Filings
Filing Date
Monday, May 12, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
2.00
7-Day Total Return
-1.37%
30-Day Total Return
28.33%
60-Day Total Return
-19.99%
90-Day Total Return
-20.07%
Year to Date Total Return
-23.00%
1-Year Total Return
-39.19%
2-Year Total Return
-57.46%
3-Year Total Return
-55.24%
5-Year Total Return
-55.12%
52-week Low
Apr 07, 2025 - $9.57
52-week High
Jul 16, 2024 - $30.41
Valuation
Market Cap
$2.09B - Mid Cap
Enterprise Value
$1.74B
Price/Sales (TTM)
3.73
Price/Book (Q)
3.06
Dividends and Shares
Shares Outstanding
134.48M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
arrowheadpharma.com
Phone Number
626 304 3400
Address
177 East Colorado Boulevard
Pasadena, CA 91105
Country
United States
Year Founded
2003
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed